When Klaus Sindahl joined Swedish biotech company Hansa Biopharma in 2019, the firm was still small, with a team of 40 people and no approved products.
Until then, and since the firm’s IPO on the Nasdaq Stockholm stock exchange in 2015, IR-related practices had been mostly outsourced, Sindahl explains, and the company was getting research coverage only through a few banks.
‘I saw an immediate need to bring communications back in-house to ensure we were relaying a consistent message while introducing the company to potential new investors and sell-side analysts,’ he tells IR Magazine.
‘We had . . .
Enjoy access to this and more – for free!
Log in or create your free My IR – Essentials account to:
- Get access to 3 free IR deep dives
- More than 100 pieces of insight, plus our exclusive CFO interviews
- Save favorites and get personalized content on your dashboard
- Enjoy 10% off all IR forums
